LTZ Therapeutics Company
LTZ develops novel immunotherapies to treat patients that suffer from cancer and other diseases with an unmet clinical need.
Founded Date:
2022-01-01
Funding Status:
Seed
Total Funding:
17000000.0
Headquarters:
San Francisco, California, United States
Last Funding Date:
2022-04-07
Investors Number:
3.0
Last Funding Type:
Seed
Industry:
Preclinical Development